Design Therapeutics (DSGN) Net Equity Issued and Repurchased (2020 - 2026)
Design Therapeutics (DSGN) posted quarterly Net Equity Issued and Repurchased of $19.9 million for Q1 2026, up 115.36% on a QoQ basis from -$129.6 million in Q2 2021.
Powered by 
Analysis
Design Therapeutics (DSGN) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Design Therapeutics has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $19.9 million in Q1 2026.
- Net Equity Issued and Repurchased for Q1 2026 came in at $19.9 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2026 was $19.9 million (changed N/A YoY), and the FY2025 annual result was $24.8 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased advanced to $19.9 million in Q1 2026, from -$129.6 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $19.9 million in Q1 2026 and troughed at $19.9 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 19.91 Mn |
| Jun 30, 2021 | -129.59 Mn |
| Mar 31, 2021 | 254.30 Mn |
| Jun 30, 2020 | 31,000.00 |
| Mar 31, 2020 | 44.70 Mn |